SCHEMBL1504502

SCHEMBL1504502

COC(=O)c1ccc(=O)n(-c2c(C)cc(Cl)cc2C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
HSD17B10 Q99714 1/20 0.41
P2RX3 P56373 1/20 0.40
ALDH1A1 P00352 5/20 0.40
USP2 O75604 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
POLB P06746 1/20 0.40
KDM4E B2RXH2 2/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 4/20 0.39
CASP3 P42574 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAPK14 Q16539 1/20 0.38
TP53 P04637 1/20 0.37
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1504738 0.86 ALDH1A1 (0.44) LMNAHSD17B10ALDH1A1TDP1KMT2A
SCHEMBL2022640 0.84 GAA (0.45) LMNAHSD17B10ALDH1A1TDP1KMT2A
SCHEMBL2028119 0.84 RXRA (0.40) HSD17B10ALDH1A1TDP1KMT2AKDM4E
SCHEMBL1504750 0.80 LMNA (0.49) LMNAHSD17B10ALDH1A1POLBKDM4E
SCHEMBL2891894 0.76 TDP1 (0.38) LMNAALDH1A1TDP1KMT2AMEN1
SCHEMBL1504127 0.74 MEN1 (0.45) LMNAALDH1A1KMT2AMEN1KDM4E
SCHEMBL1504529 0.74 ALDH1A1 (0.46) LMNAHSD17B10ALDH1A1TDP1KMT2A
SCHEMBL1504547 0.74 ALDH1A1 (0.47) LMNAHSD17B10ALDH1A1TDP1POLB
SCHEMBL2944620 0.72 LMNA (0.53) LMNAHSD17B10P2RX3ALDH1A1TDP1
SCHEMBL24849951 0.72 ALDH1A1 (0.47) LMNAHSD17B10P2RX3ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173684-B2 Pyridone derivatives as p38α MAPK inhibitors ASTELLAS PHARMA INC. (JP) 2012-05-08 US disclosed
EP-2155683-B1 PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS ASTELLAS PHARMA INC (JP) 2011-03-16 EP disclosed
US-20100063098-A1 PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS ASTELLAS PHARMA INC. (JP) 2010-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063098-A1 PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS MAPK1, MAPK6, MAPK3 LMNA 2734/4885HSD17B10 783/4885P2RX3 1116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.